Itamar Medical's Endo-PAT2000 Approved For Use by Australian Government's TGA

Dec. 17, 2008 - PRLog -- Caesarea, Israel - Itamar Medical, an international medical technology company developing  noninvasive diagnostic systems using the Peripheral Arterial Tone (PAT™) signal, announced today that it has received TGA clearance for the Endo-PAT2000, certifying the Endo-PAT2000 for use and distribution in Australia. Itamar Medical has developed the first simple, inexpensive, office-based diagnostic test for endothelial function. The Endo-PAT2000 is a noninvasive device that measures endothelial function, the earliest clinically detectable stage of cardiovascular disease, using bio-sensors mounted on patients’ fingers that measure minute changes in vascular tone using Itamar Medical's PAT Signal technology.

The Endo-PAT2000 adds an unparalleled dimension to the prevention of cardiovascular disease by enabling physicians to accurately measure endothelial function and modify patient management accordingly. The medical community has long sought a cost-effective and reliable method to detect endothelial dysfunction. Itamar Medical's Endo-PAT2000 meets this challenge, enhancing the traditional clinical settings’ diagnostic capabilities for endothelial dysfunction. The Endo-PAT2000 can be used in any setting, from hospital bedside to outpatient clinic.

"Itamar Medical is proud to bring our innovative PAT Technology to the medically-advanced Australian market," said Dov Rubin, President and CEO of Itamar Medical. "This is an important milestone for the Endo-PAT2000and for Itamar Medical's penetration into the Asia Pacific markets."

Lorrence Platania, Managing Director of JLM Accutek Healthcare, the authorized Endo-PAT2000 Australian distributor stated, "We are thrilled to partner with Itamar Medical to bring the Endo-PAT2000 to Australia. This certification paves the way for patients in Australia to get tested with the Endo-PAT2000, providing them with a comprehensive picture of their endothelial cell function, a critical factor in cardiac health."

Itamar Medical (TASE: ITMR) is a medical technology company developing noninvasive diagnostic systems using Peripheral Arterial Tone (PAT™) signal, including the Watch-PAT™ systems for the diagnosis of sleep related breathing disorders and the Endo-PAT™ systems for assessment of endothelial function, a condition recognized as an early stage of cardiovascular and cerebrovascular diseases.  For further information see http://www.itamar-medical.com.


Media Contacts

Marissa Levy
Account Executive
NCSM Strategic Marketing
+972-2-563-7527
Marissa@ncsm.co.il

Livnat Zvili-Ojalvo
Itamar Medical
Marketing and Sales Coordinator
+972-4-617-7000
Zlivnat@itamar-medical.com